Arbutus Biopharma (ABUS) Cash from Investing Activities (2013 - 2026)

Arbutus Biopharma has reported Cash from Investing Activities for 14 years, with the latest figure at $2.2 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 80.62% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (down 71.55% YoY) and the FY2025 annual result came in at $15.6 million, down 32.11% from the prior year.
• Cash from Investing Activities improved to $2.2 million in Q1 2026 per ABUS's latest filing, from -$1.4 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $22.2 million in Q4 2023 and troughed at -$60.1 million in Q1 2022.
• A 5-year average of $974000.0 and a median of $9.8 million in 2024 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities tumbled 429.6% in 2022, then soared 582.1% in 2024.
• Over 5 years, Cash from Investing Activities stood at $12.7 million in 2022, then jumped by 75.25% to $22.2 million in 2023, then sank by 39.66% to $13.4 million in 2024, then tumbled by 110.15% to -$1.4 million in 2025, then jumped by 261.57% to $2.2 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $2.2 million, -$1.4 million, and -$10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.